67-year-old male with no significant medical history was admitted with complaints of chronic fatigue, splenomegaly, and gingival bleeding for the past six months. On admission, our patient was pancytopenic with a critical platelet count of 15K and mean corpuscular volume of 102. Work-up for medication-induced, infectious, and malignant etiologies were pursued. A peripheral blood smear ( Figure 1 ) and bone marrow aspirate ( Figure 2 ) were obtained revealing characteristic promyelocytes with multiple Auer rods (faggot cells) on smear and increased immature granulocytes, as seen on aspirate, indicative of the hypergranular form of acute promyelocytic leukemia (FAB-M3) [1] . The patient was started on induction therapy using all-trans retinoic acid (ATRA) and concurrent arsenic trioxide therapy after Figure 1: Smear auer rods.
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67-year-old male with no significant medical history was admitted with complaints of chronic fatigue, splenomegaly, and gingival bleeding for the past six months. On admission, our patient was pancytopenic with a critical platelet count of 15K and mean corpuscular volume of 102. Work-up for medication-induced, infectious, and malignant etiologies were pursued. A peripheral blood smear ( Figure 1 ) and bone marrow aspirate ( Figure 2 ) were obtained revealing characteristic promyelocytes with multiple Auer rods (faggot cells) on smear and increased immature granulocytes, as seen on aspirate, indicative of the hypergranular form of acute promyelocytic leukemia (FAB-M3) [1] . The patient was started on induction therapy using all-trans retinoic acid (ATRA) and concurrent arsenic trioxide therapy after 48 hours [2] . Additional concerns for differentiation syndrome, due to hyperleukocytosis [3] , and disseminated intravascular coagulation (DIC) [4] were present and monitored closely. Follow up cytology confirmed t(15;17,q22,q12) promyelocytic leukemia and retinoic acid receptor-alpha (PML:RARA) gene translocation. Our patient was transfused with leukocyte-reduced platelets, cryoprecipitate [3] , and packed red blood cells as needed until appropriate blood counts were attained. Due to the precipitous rise in WBC count (from 2K to 72K), the patient was transitioned to ATRA plus anthracyclin-based (e.g., daunorubicin, cytarabine) chemotherapy in place of arsenic trioxide. Total therapy includes two cycles of additional consolidation treatment and ATRA maintenance [5] .
